Insights Into NTRK Gene Fusion-Positive Thyroid Cancer
Perspectives on drivers in treatment pathways for NTRK fusion-positive cancers
Southwest – March 29, 2022
Faculty Chair
Lori Wirth, MD
Massachusetts General Hospital Center for Head and Neck Cancers
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
REPORT SNAPSHOT
- A moderated roundtable discussion was held with community oncologists from the Southwest US region in a virtual setting on March 29, 2022
- Disease-state and data presentations were led by Dr Lori Wirth, Medical Director of Massachusetts General Hospital Center for Head and Neck Cancers, in conjunction with content developed by the Aptitude Health clinical team
- Insights were obtained on the thyroid cancer disease landscape in the community setting, specifically testing protocols and treatment pathways for NTRK gene fusion-positive thyroid cancer
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
- The group of advisors comprises 13 oncologists from Arizona, California, Colorado, New Mexico, Nevada, and Utah
